ISDA

Entry Detail

PDB ID:

4O04

Keywords:

Title:

Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2013-12-13

Release Date:

2014-12-24

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.82 Å

R-Value Free:

0.20

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

I 2 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Heat shock protein HSP 90-alpha
Chain IDs:A
Chain Length:233
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P07900 Pfam ID:PF13589 EC:3.6.4.10

Ligand Molecules

2Q8

Primary Citation

Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.

Ernst, J.T, Neubert, T, Liu, M, Sperry, S, Zuccola, H, Turnbull, A, Fleck, B, Kargo, W, Woody, L, Chiang, P, Tran, D, Chen, W, Snyder, P, Alcacio, T, Nezami, A, Reynolds, J, Alvi, K, Goulet, L, Stamos, D.Show

J.Med.Chem. 57 3382 3400 (2014)

PMID: 24673104 DOI: 10.1021/jm500042s

Abstact

A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity versus the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, respectively). Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntingtin protein (mHtt) in vitro, however with less cellular toxicity. Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD). A potent, selective, orally available HSP90α/β inhibitor was identified (compound 31) that crosses the blood-brain barrier. Compound 31 demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.

Legend

Protein

Chemical

Disease

Primary Citation of related structures